InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Tectonic Therapeutic, Inc.

TECX Clue Score49
United States Fiscal year ends December CIK 0001681087 Results filed 6 Aug 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

62
Insider
Date
Role
Action
Shares
Price
Amount
Alise Reicin
26 Oct 2026
Chief Executive Officer
Exercised, kept
10,000
$2.38
$23.80K
Peter McNamara
30 Sep 2026
Chief Scientific Officer
Sold on a plan
536
$23.04
$12.35K
Peter McNamara
25 Aug 2026
Chief Scientific Officer
Sold after exercise
43
$36.52
$1.57K
Peter McNamara
12 Aug 2026
Chief Scientific Officer
Sold after exercise
43
$35.00
$1.51K
Peter McNamara
30 Jun 2026
Chief Scientific Officer
Sold after exercise
172
$35.00
$6.02K
Marcella K. Ruddy
4 May 2026
Chief Medical Officer
Sold on a plan
1,065
$30.00
$31.95K
Marcella K. Ruddy
1 Apr 2026
Chief Medical Officer
Sold on a plan
1,000
$31.05
$31.05K
Peter McNamara
6 Mar 2026
Chief Scientific Officer
Sold after exercise
215
$35.00
$7.53K
Peter McNamara
6 Mar 2026
Chief Scientific Officer
Sold after exercise
6,047
$30.00
$181.41K
Marcella K. Ruddy
6 Mar 2026
Chief Medical Officer
Sold on a plan
10,000
$30.00
$300.00K
Peter McNamara
4 Mar 2026
Chief Scientific Officer
Sold on a plan
1,650
$25.00
$41.25K
Peter McNamara
3 Mar 2026
Chief Scientific Officer
Sold on a plan
1,649
$22.06
$36.38K
Alise Reicin
11 Feb 2026
Chief Executive Officer
Buy
2,500
$21.10
$52.75K
Daniel Lochner
10 Feb 2026
Chief Financial Officer
Buy
6,000
$21.61
$129.66K
Marc Schwabish
10 Feb 2026
Chief Business Officer
Exercised, kept
4,500
$2.38
$10.71K
Alise Reicin
31 Dec 2025
Chief Executive Officer
Exercised, kept
10,966
$2.38
$26.10K
Peter McNamara
22 Dec 2025
Chief Scientific Officer
Exercised, kept
7,000
$2.98
$20.86K
Timothy A Springer
11 Apr 2025
Director
Buy indirect
53,706
$16.31
$875.94K
Timothy A Springer
11 Apr 2025
Director
Buy
9,478
$16.31
$154.59K
Timothy A Springer
10 Apr 2025
Director
Buy indirect
45,858
$16.73
$767.20K
Timothy A Springer
10 Apr 2025
Director
Buy
8,092
$16.73
$135.38K
Timothy A Springer
9 Apr 2025
Director
Buy indirect
4,856
$15.23
$73.96K
Timothy A Springer
9 Apr 2025
Director
Buy indirect
16,215
$14.62
$237.06K
Timothy A Springer
9 Apr 2025
Director
Buy
857
$15.23
$13.05K
Timothy A Springer
9 Apr 2025
Director
Buy
2,861
$14.62
$41.83K
Terrance McGuire
7 Apr 2025
Director
Sell indirect
500,000
$17.10
$8.55M
Timothy A Springer
7 Apr 2025
Director
Buy indirect
412,500
$17.10
$7.05M
Timothy A Springer
7 Apr 2025
Director
Buy
87,500
$17.10
$1.50M
Daniel Lochner
5 Feb 2025
Chief Financial Officer
Buy
4,617
$54.14
$249.96K
Timothy A Springer
5 Feb 2025
Director
Buy indirect
660,000
$50.00
$33.00M
Timothy A Springer
5 Feb 2025
Director
Buy
129,294
$54.14
$7.00M
Marc Schwabish
28 Jan 2025
Chief Business Officer
Exercised, kept
2,700
$2.38
$6.43K
Marc Schwabish
9 Dec 2024
Chief Business Officer
Exercised, kept
2,000
$2.38
$4.76K
Peter McNamara
3 Dec 2024
Chief Scientific Officer
Exercised, kept
3,500
$2.38
$8.33K
Timothy A Springer
22 Oct 2024
Director
Buy
300,000
$33.59
$10.08M
Timothy A Springer
26 Sep 2024
Director
Buy
2,400
$30.87
$74.09K
Timothy A Springer
26 Sep 2024
Director
Buy
4,070
$30.10
$122.51K
Timothy A Springer
26 Sep 2024
Director
Buy
18,999
$29.13
$553.44K
Timothy A Springer
26 Sep 2024
Director
Buy
24,531
$28.16
$690.79K
Braden Michael Leonard
14 May 2024
10% owner
Buy indirect
296,882
$1.30
$385.95K
Braden Michael Leonard
13 May 2024
10% owner
Buy indirect
216,053
$1.26
$272.23K
Braden Michael Leonard
13 May 2024
10% owner
Buy indirect
253,700
$1.24
$313.32K
Geoffrey Mackay
24 Jan 2023
President & CEO
Exercised, kept
45,999
$0.91
$41.86K
Geoffrey Mackay
23 Dec 2022
President & CEO
Exercised, kept
142,013
$0.41
$58.68K
Philip J. Vickers
7 Jul 2021
Director
Buy
4,800
$8.35
$40.08K
Phillip B. Donenberg
17 Feb 2021
Director
Buy
2,000
$11.71
$23.42K
Geoffrey Mackay
24 Dec 2020
President & CEO
Exercised, kept
100,000
$0.41
$41.32K
Geoffrey Mackay
12 Feb 2020
See Remarks
Sell
1,400
$29.07
$40.69K
Geoffrey Mackay
11 Feb 2020
See Remarks
Sell
18,404
$28.10
$517.10K
Geoffrey Mackay
11 Feb 2020
See Remarks
Sell
44,596
$27.36
$1.22M
Christopher Paige
11 Feb 2020
Director
Sell
15,000
$28.00
$420.00K
Christopher Paige
28 Jan 2020
Director
Sell
10,000
$23.00
$230.00K
Bruce Booth
19 Jul 2019
Director
Buy indirect
810,811
$18.50
$15.00M
Atlas Venture Fund X, L.P.
19 Jul 2019
10% owner
Buy indirect
810,811
$18.50
$15.00M
Geoffrey Mackay
8 Apr 2019
See Remarks
Sell
698
$27.07
$18.89K
Christopher Paige
8 Apr 2019
Director
Sell
100
$26.92
$2.69K
Christopher Paige
8 Apr 2019
Director
Sell
2,400
$25.84
$62.02K
Geoffrey Mackay
5 Apr 2019
See Remarks
Sell
13,302
$27.26
$362.62K
Christopher Paige
5 Apr 2019
Director
Sell
867
$26.21
$22.72K
Christopher Paige
5 Apr 2019
Director
Sell
6,633
$25.59
$169.76K
Nerissa Kreher
8 Oct 2018
Chief Medical Officer
Exercised, kept
2,942
$0.91
$2.68K
Katina Dorton
8 Oct 2018
Chief Financial Officer
Exercised, kept
10,000
$0.91
$9.10K

What was left out

Form 4 filings counted 184
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 6
Sales straight out of an exercise 5
Sales at will 12
Transactions with no price 0
Shares from compensation/vesting 32,689,931
Sales filed before the plan box existed 11
History held since 22 Jun 2018